BioSpace News Archive

West Pharmaceutical Services today announced that the Company’s Board of Directors has approved a first-quarter 2018 dividend of $0.14 per share.

STEGLATRO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Pending approval, Arrowhead intends to proceed with AROHBV1001, a Phase 1/2 single-dose escalation study to evaluate the safety, tolerability, and pharmacokinetic effects of ARO-HBV in healthy adult volunteers

Novartis announced today the FDA has accepted the Company’s supplemental sNDA for filing, and granted Priority Review designation for Tafinlar in combination with Mekinist for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, following complete resection.

During this time, the California Department of Public Health will review CSPA’s application and corresponding municipal permits and documentation for a permanent license.

La Jolla announced that the FDA has approved Giapreza to increase blood pressure in adults with septic or other distributive shock.

Antares Pharma today announced that a written request for a Type A meeting, along with a comprehensive briefing document, have been submitted to the FDA, in response to the CRL received by Antares.

Glycotope today announces it has enrolled the first patient in its international GATTO study which combines two of the Company’s immuno-oncology assets derived from its world-leading glycobiology expertise.

The Vanguard Forum for Healthcare Leaders invited AIT Bioscience CEO Terri Pascarelli to serve as a faculty member at its November 2017 event in New York City, NY.

Lumify is the only over-the-counter eye drop with low-dose brimonidine for the treatment of eye redness.